![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, July 15, 2014 8:45:09 PM
It is very, very, very hard to launch and sustain a product like this; high risk, high cost, unproven metrics, additional surgical training, duplication with existing methods, etc., etc.. daVinci was in many ways lucky, but had no competition. Titan has entrenched competition; it's called da Vinci. And ISRG has the resources to change the playing field any way they want to, even pricing. People will not flock to SPORT, FOR ONE PROCEDURE.
Titan needs to be developing, at least in theory, where it will evolve even as it launches. Doing the detail work in secret is fine, but the medical amd investment sphere need to have something to pin a future use(s) onto.
I've seen and been involved with potential medical products developed by the finest doctors, medical centers, tech transfer departments, and universities - only to flounder because the market had no friggin' idea what they would be good for.
Just a warning: Titan needs to promote its purpose, or just wind up as a takeover technology. Fine by me if the price is good.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM